Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Lianxiang Luo, Tong Wu, Miaorong Ji, Jing Xiang, Youwen Zou, Yinglin Liao
Lung cancer is a serious health issue globally, and current treatments have proven to be inadequate. Therefore, immune checkpoint inhibitors (ICIs) that target the PD-1/PD-L1 pathway have become a viable treatment option in lun cancer. Honokiol, a lignan derived from Magnolia officinalis, has been found to possess anti-inflammatory, antioxidant, and antitumor properties. Our research found that honokiol can effectively regulate PD-L1 through network pharmacology and transcriptome analysis. Cell experiments showed that honokiol can significantly reduce PD-L1 expression in cells with high PD-L1 expression...
April 15, 2024: International Immunopharmacology
#22
JOURNAL ARTICLE
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Nina Wyss, Fiamma Berner, Vincent Walter, Ann-Kristin Jochum, Mette T Purde, Marie-Therese Abdou, Tobias Sinnberg, Kathrin Hofmeister, Oltin T Pop, Omar Hasan Ali, Jens Bauer, Hung-Wei Cheng, Mechthild Lütge, Niklas Klümper, Stefan Diem, Zeynep Kosaloglu-Yalcin, Yizheng Zhang, Laura Sellmer, Boris Macek, Julia Karbach, David König, Heinz Läubli, Lars Zender, Britta S Meyer, Christoph Driessen, Christian M Schürch, Wolfram Jochum, Teresa Amaral, Lucie Heinzerling, Antonio Cozzio, Ahmed N Hegazy, Tino Schneider, Martin H Brutsche, Alessandro Sette, Tobias L Lenz, Juliane Walz, Hans-Georg Rammensee, Martin Früh, Elke Jäger, Burkhard Becher, Amanda Tufman, Nicolas Nuñez, Markus Joerger, Lukas Flatz
RATIONALE: Immune checkpoint inhibitor-related pneumonitis is a serious autoimmune event affecting up to 20% of patients with non-small cell lung cancer, yet the factors underpinning its development in some patients and not others are poorly understood. OBJECTIVES: To investigate the role of autoantibodies and autoreactive T cells against surfactant-related proteins in the development of pneumonitis. METHODS: The study cohort consisted of non-small cell lung cancer patients who gave blood samples before and during immune checkpoint inhibitor treatment...
April 16, 2024: American Journal of Respiratory and Critical Care Medicine
#23
JOURNAL ARTICLE
Francis Ntwali, Quentin Gilliaux, Patrick M Honoré
BACKGROUND CRS (cytokine release syndrome) is a massive activation of the inflammatory system characterized by a supra-physiological rate of inflammatory cytokines. The interleukin 6 cytokine plays a central role in CRS. The main clinical sign of CRS is fever, but CRS can lead to multiple organ failure in severe cases. CRS is usually described in sepsis, more recently in SARS COV-2 infection, and in chimeric antigen receptor T-cell therapy. However, it can also be associated with immune checkpoint inhibitors (ICIs), which is infrequently described...
April 16, 2024: American Journal of Case Reports
#24
JOURNAL ARTICLE
Giuseppe Luigi Banna, Mona Ali Hassan, Alessio Signori, Emilio Francesco Giunta, Akash Maniam, Shobana Anpalakhan, Shyamika Acharige, Aruni Ghose, Alfredo Addeo
IMPORTANCE: Randomized clinical trials (RCTs) with neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy (ICI-chemotherapy) for patients with early-stage non-small cell lung cancer (NSCLC) have reported consistent associations with event-free survival (EFS) and pathologic complete response (pCR) pending longer follow-up for overall survival data. OBJECTIVE: To assess the pooled benefit of ICI-chemotherapy in 2-year EFS and pCR among patients with NSCLC and examine the impact of clinical, pathologic, and treatment-related factors...
April 1, 2024: JAMA Network Open
#25
REVIEW
Azadeh Eskandari, Thean Chor Leow, Mohd Basyaruddin Abdul Rahman, Siti Nurbaya Oslan
Over the past few decades, cancer immunotherapy has experienced a significant revolution due to the advancements in immune checkpoint inhibitors (ICIs) and adoptive cell therapies (ACTs), along with their regulatory approvals. In recent times, there has been hope in the effectiveness of cancer vaccines for therapy as they have been able to stimulate de novo T-cell reactions against tumor antigens. These tumor antigens include both tumor-associated antigen (TAA) and tumor-specific antigen (TSA). Nevertheless, the constant quest to fully achieve these abilities persists...
April 16, 2024: Molecular Biotechnology
#26
JOURNAL ARTICLE
Chuang Yang, Tiantian Xuan, Qing Gong, Xin Dai, Chengjun Wang, Rongyu Zhang, Wen Zhao, Jian Wang, Weiming Yue, Jisheng Li
BACKGROUND: Patients with extensive-stage small cell lung cancer (ES-SCLC) have an exceptionally poor prognosis and immune checkpoint inhibitors (ICIs) combined with etoposide-platinum is recommended as standard first-line therapy. However, which combination pattern is the best still remains unknown. This network meta-analysis was performed to compare the efficacy and safety of currently available patterns including an antiangiogenic agent containing regimen and probed into the most appropriate therapy for patients...
April 16, 2024: Thoracic Cancer
#27
JOURNAL ARTICLE
Ken Yamamoto, Taira Ninomaru, Hideaki Okada, Katsuya Hirano, Temiko Shimada, Akito Hata
In non-small-cell lung cancer, continuous immune-checkpoint inhibitors (ICIs) beyond progression are often used in clinical practice. On the other hand, there is almost no data on whether the concept of continuous ICIs beyond progression can be adopted in small-cell lung cancer (SCLC). We describe the effectiveness of continuous ICIs beyond progression in SCLC. Medical courses of SCLC patients treated with chemo-immunotherapy were retrospectively reviewed at our hospital. The study included 36 patients with a median age of 73 years (range 46-83 years) who introduced chemo-immunotherapy between September 2019 and December 2022...
April 16, 2024: Thoracic Cancer
#28
REVIEW
Cheng-Long Han, Bao-Wen Tian, Lun-Jie Yan, Zi-Niu Ding, Hui Liu, Guo-Qiang Pan, Xiao Zhang, Xin-Chen Mao, Si-Yu Tan, Rui-Zhe Li, Dong-Xu Wang, Zhao-Ru Dong, Yu-Chuan Yan, Tao Li
BACKGROUND: The effect of age, sex, and eastern cooperative oncology group performance status (ECOG PS) on the efficacy and safety of immune checkpoint inhibitor (ICI) therapy among hepatocellular carcinoma (HCC) patients remains elusive. Thus, a meta-analysis was conducted to evaluate whether such effects exist. RESEARCH DESIGN AND METHODS: Eligible studies in PubMed, Embase, and Cochrane Library databases were retrieved. RESULTS: One-hundred-and-eleven studies involving 14,768 HCC patients were included...
April 16, 2024: Expert Review of Anticancer Therapy
#29
Doah Kim, Jeong Kyeong Jang, Youngje Sung
INTRODUCTION: Given the recent additions of immune checkpoint inhibitors (ICIs) to various cancer treatments, adverse effects, especially involving the eyes, have been on the rise. Here, we report an acute exacerbation of cancer-associated retinopathy (CAR) triggered by durvalumab treatment of small-cell lung cancer (SCLC). CASE PRESENTATION: An 81-year-old Asian male complained of a scotoma in the left eye after durvalumab administration, to treat SCLC. Humphrey visual field examination revealed a C-shaped temporal scotoma...
2024: Case Reports in Ophthalmology
#30
REVIEW
Siwei Yang, Xianrui Yang, Zekai Hou, Liang Zhu, Zhili Yao, Yifei Zhang, Yanzhuo Chen, Jie Teng, Cheng Fang, Songmao Chen, Mingfei Jia, Zhifei Liu, Shaosan Kang, Yegang Chen, Gang Li, Yuanjie Niu, Qiliang Cai
Renal cell carcinoma (RCC) is a frequent urological malignancy characterized by a high rate of metastasis and lethality. The treatment strategy for advanced RCC has moved through multiple iterations over the past three decades. Initially, cytokine treatment was the only systemic treatment option for patients with RCC. With the development of medicine, antiangiogenic agents targeting vascular endothelial growth factor and mammalian target of rapamycin and immunotherapy, immune checkpoint inhibitors (ICIs) have emerged and received several achievements in the therapeutics of advanced RCC...
April 15, 2024: Heliyon
#31
JOURNAL ARTICLE
Jun Yamada, Takafumi Fukui, Atsuhiko Yatani, Chihiro Mimura, Kiyoko Fukuda, Daisuke Hazama, Naoko Katsurada, Tatsuya Nagano, Masatsugu Yamamoto, Motoko Tachihara
BACKGROUND: There have been reports on the impact of concurrent drugs on the outcome of immunotherapy for non-small cell lung carcinoma (NSCLC). However, the effect of some drugs, such as antibiotics and nonsteroidal anti-inflammatory drugs (NSAIDs), has not been clarified in patients with NSCLC. In the present study, we aimed to assess the association between concurrent drugs and the outcomes of immune checkpoint inhibitors (ICIs) alone or in combination with chemotherapy for patients with advanced NSCLC...
April 15, 2024: Thoracic Cancer
#32
JOURNAL ARTICLE
Mark E Harrison, Nicolas J Deere, Muhammad Ali Imron, Darmae Nasir, Adul, Hastin Ambar Asti, Joana Aragay Soler, Nicholas C Boyd, Susan M Cheyne, Sarah A Collins, Laura J D'Arcy, Wendy M Erb, Hannah Green, William Healy, Hendri, Brendan Holly, Peter R Houlihan, Simon J Husson, Iwan, Karen A Jeffers, Ici P Kulu, Kitso Kusin, Nicholas C Marchant, Helen C Morrogh-Bernard, Susan E Page, Ari Purwanto, Bernat Ripoll Capilla, Oscar Rodriguez de Rivera Ortega, Santiano, Katie L Spencer, Jito Sugardjito, Jatna Supriatna, Sara A Thornton, F J Frank van Veen, Yulintine, Matthew J Struebig
Uncontrolled fires place considerable burdens on forest ecosystems, compromising our ability to meet conservation and restoration goals. A poor understanding of the impacts of fire on ecosystems and their biodiversity exacerbates this challenge, particularly in tropical regions where few studies have applied consistent analytical techniques to examine a broad range of ecological impacts over multiyear time frames. We compiled 16 y of data on ecosystem properties (17 variables) and biodiversity (21 variables) from a tropical peatland in Indonesia to assess fire impacts and infer the potential for recovery...
April 23, 2024: Proceedings of the National Academy of Sciences of the United States of America
#33
JOURNAL ARTICLE
Xuemeng Li, Fang Yang, Baogang Liu, Leiguang Ye, Jingwen Du, Xiaona Fan, Yue Yu, Mengwei Li, Li Bu, Zhuoqi Zhang, Lili Xie, Wuquan Li, Jiaqing Qi
Immune-related adverse effects can lead to damage to various systems of the body, checkpoint inhibitor-associated pneumonitis (CIP) is one of the potentially lethal immune-related adverse effects. However, evidence regarding the risk factors associated with CIP is limited. To timely and accurate identification and prompt treatment of CIP, understanding the risk factors for multimorbidity among diverse study populations becomes crucial. We retrospectively analyzed the clinical data of 1131 patients with lung cancer receiving immunotherapy to identify 110 patients with CIP, the clinical characteristics and radiographic features of patients with CIP were analyzed...
April 15, 2024: Journal of Immunotherapy
#34
JOURNAL ARTICLE
Sunyin Rao, Li Min, Jie Zhao, Juan Su, Lianhua Ye
Chemoradiotherapy (CRT) followed by consolidation of immune checkpoint inhibitors (ICIs), such as durvalumab or pembrolizumab, for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) with tumor PD-L1 expression <1% remains a topic of controversy. Previous studies from PubMed, Cochrane Library and Embase databases were searched for a meta-analysis. A total of 16 studies were included in part one of the meta-analysis and it was observed that consolidation of ICIs after CRT improved overall survival (OS) [hazard ratio (HR) 1...
June 2024: Oncology Letters
#35
JOURNAL ARTICLE
Xiaoya Xu, Xiangru Shi, Dingjie Zhou, Dedong Cao
OBJECTIVE: This study aimed to assess the clinical value of the modified albumin-bilirubin (mALBI) grade in predicting the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy. METHODS: We conducted a retrospective cohort study of patients with advanced NSCLC who received immune checkpoint inhibitors (ICIs) from January 2020 to May 2022. The primary endpoints were overall survival (OS), treatment response, and the association between different mALBI grades and survival...
March 2024: Curēus
#36
REVIEW
Xinran Gao, Jingting Jiang
Serving as a pivotal immunotherapeutic approach against tumors, anti-PD-1/PD-L1 therapy amplifies the immune cells' capability to eliminate tumors by obstructing the interaction between PD-1 and PD-L1. Research indicates that immune checkpoint inhibitors are effective when a patient's gut harbors unique beneficial bacteria. As such, it has further been revealed that the gut microbiome influences tumor development and the efficacy of cancer treatments, with metabolites produced by the microbiome playing a regulatory role in the antitumor efficacy of Immune checkpoint inhibitors(ICBs)...
2024: Frontiers in Immunology
#37
Lijuan He, Haiyuan Li, Yunpeng Wang, Weidong Li, Lei Gao, Bo Xu, Jike Hu, Puyi He, Weigao Pu, Guodong Sun, Zhuanfang Wang, Qinying Han, Ben Liu, Hao Chen
Metastatic colon cancer remains an incurable disease, and it is difficult for existing treatments to achieve the desired clinical outcome, especially for colon cancer patients who have received first-line treatment. Although immune checkpoint inhibitors (ICIs) have demonstrated durable clinical efficacy in a variety of solid tumors, their response requires an inflammatory tumor microenvironment. However, microsatellite-stable ( MSS ) colon cancer, which accounts for the majority of colorectal cancers, is a cold tumor that does not respond well to ICIs...
2024: Frontiers in Immunology
#38
REVIEW
Meng-Ru Zhang, Lin-Lin Fang, Yang Guo, Qin Wang, You-Jie Li, Hong-Fang Sun, Shu-Yang Xie, Yan Liang
Cancer immunotherapy has emerged as a novel therapeutic approach against tumors, with immune checkpoint inhibitors (ICIs) making significant clinical practice. The traditional ICIs, PD-1 and PD-L1, augment the cytotoxic function of T cells through the inhibition of tumor immune evasion pathways, ultimately leading to the initiation of an antitumor immune response. However, the clinical implementation of ICIs encounters obstacles stemming from the existence of an immunosuppressive tumor microenvironment and inadequate infiltration of CD8+ T cells...
2024: International Journal of Nanomedicine
#39
JOURNAL ARTICLE
Yohei Kawaguchi, Nanako Nishioka, Taiyo Nakamura, Kentaro Imai, Takuya Aoki, Naohiro Kajiwara, Norihiko Ikeda
BACKGROUND: The effect of lymph node dissection (LND) on the efficacy of immune checkpoint inhibitor (ICI) remains unclear. The purpose of this study was to examine the difference in the effect of ICI between patients with non-small cell lung cancer (NSCLC) according to the extent of LND performed in surgery prior to postoperative recurrence. METHODS: A total of 134 patients with postoperative recurrence (surgery group, n=26) or unresectable advanced lung cancer (non-surgery group, n=108) who were treated with ICIs between January 2016 and December 2022 were included for analysis...
March 29, 2024: Journal of Thoracic Disease
#40
JOURNAL ARTICLE
Xiaoqi Yan, Luqing Zhao, Fei Wu, Bo Shen, Guoren Zhou, Jifeng Feng, Chao Yue, Jingni Zhu, Shaorong Yu
BACKGROUND: Immune checkpoint inhibitors (ICIs) have dramatically changed the first-line treatment pattern of non-small cell lung cancer (NSCLC) without driver gene alterations. However, the optimal choice for second-line treatment after initial treatment with ICIs is unclear. This study aimed to clarify the efficacy and safety of ICI rechallenge therapy in locally advanced and advanced NSCLC. METHODS: We retrospectively analyzed the histories of 224 patients with locally advanced or advanced NSCLC treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors alone or in combination with chemotherapy and/or antiangiogenic therapy in first-line treatment...
March 29, 2024: Journal of Thoracic Disease
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
